131 related articles for article (PubMed ID: 23035595)
1. Emerging nanodelivery strategies of RNAi molecules for colon cancer therapy: preclinical developments.
Binkhathlan Z; Alshamsan A
Ther Deliv; 2012 Sep; 3(9):1117-30. PubMed ID: 23035595
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
3. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
4. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
5. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
6. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
[TBL] [Abstract][Full Text] [Related]
7. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
8. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.
Lage H
Curr Drug Targets; 2006 Jul; 7(7):813-21. PubMed ID: 16842213
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Drug Resistance in Colon Cancer by Aptamer-Mediated Targeted Co-Delivery of Drug and siRNA Using Grapefruit-Derived Nanovectors.
Yan W; Tao M; Jiang B; Yao M; Jun Y; Dai W; Tang Z; Gao Y; Zhang L; Chen X; Wang QL
Cell Physiol Biochem; 2018; 50(1):79-91. PubMed ID: 30278432
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids as P-gp Inhibitors: A Systematic Review of SARs.
Cui J; Liu X; Chow LMC
Curr Med Chem; 2019; 26(25):4799-4831. PubMed ID: 30277144
[TBL] [Abstract][Full Text] [Related]
11. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
12. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
Abbasi M; Lavasanifar A; Uludag H
Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
14. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery.
Kou L; Sun R; Bhutia YD; Yao Q; Chen R
Expert Opin Drug Deliv; 2018 Sep; 15(9):869-879. PubMed ID: 30169976
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
16. Physiological modulation approaches to improve cancer chemotherapy : a review.
Kumar R; Kaur M; Silakari O
Anticancer Agents Med Chem; 2014 Jun; 14(5):713-49. PubMed ID: 24117110
[TBL] [Abstract][Full Text] [Related]
17. P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update.
Yang X; Liu K
Curr Drug Metab; 2016; 17(8):806-826. PubMed ID: 27364832
[TBL] [Abstract][Full Text] [Related]
18. Colon adenocarcinoma multidrug resistance reverted by Euphorbia diterpenes: structure-activity relationships and pharmacophore modeling.
Reis M; Ferreira RJ; Serly J; Duarte N; Madureira AM; Santos DJ; Molnár J; Ferreira MJ
Anticancer Agents Med Chem; 2012 Nov; 12(9):1015-24. PubMed ID: 22583416
[TBL] [Abstract][Full Text] [Related]
19. RNA interference in the treatment of colon cancer.
Prados J; Melguizo C; Roldan H; Alvarez PJ; Ortiz R; Arias JL; Aranega A
BioDrugs; 2013 Aug; 27(4):317-27. PubMed ID: 23553339
[TBL] [Abstract][Full Text] [Related]
20. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
